DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20183074

Study of proportion and pattern of adverse drug events among patients coming to health centers in urban and rural areas

P. B. Tarun Teja, Balaji Ramraj

Abstract


Background: Adverse drug events (ADE) are rated as the fifth leading cause of death among all diseases. Approximately 5-8% of all hospitalization worldwide is due to ADE. The present study was conducted with the aim of analyzing the pattern of Adverse Drug events in patients coming to urban and rural health care centres, their manifestations and severity.

Methods: The study type useful in this study was cross sectional study. This method is helpful to find the exact duration of occurrence of ADE after administration of drug and to know what kind of adverse event patient is suffering from.

Results: There are many studies done in peripheral health care centres regarding ADE in India. In our study, out of 250 patients, 125 were from urban and 125 were from rural. Among the 125 patients from urban 3.2% (4 cases) adverse drug events- reported. Among the 125 patients from rural 4% (5 cases)adverse drug events- reported.

Conclusions: This study provides a baseline idea about the knowledge and perception toward ADEs among patients visiting an outpatient department at urban and rural hospital in India. Respondents were unaware about the process of reporting ADEs, reporting by the consumers, and the possible benefits to them by doing so. There is a strong need to do the work to make consumers aware about the same. Educational interventions are needed to improve awareness among patients regarding importance of ADE reporting.

 


Keywords


Adverse drug events, Peripheral health care centres, Urban and rural population

Full Text:

PDF

References


Phatak A, Nagari BG. Safety of medicines. Pharma Times. 2003;35:19–21.

Vikas D, Sindhu S, Anand KS. Adverse drug reaction monitoring in India. JIACM. 2004;5(1):27–33.

Munir P, Brecken Alasdair M. Clinical review – Adverse drug reaction. BMJ. 1998;316(25):1295–8.

Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in south India. Perspect Clin Res. 2015;6(1):45–52.

Rehan HS, Vasudev K, Tripathi CD. Adverse drug reaction monitoring: knowledge, attitude and practices of medical students and prescribers. Natl Med J India. 2002;15:24–6.

Jha N, Ratthore DS, Shankar PR, Gyawali S. Pharmacovigilance knowledge among patients at a teaching hospital in Lalitpur district, Nepal. J Clin Diagn Res. 2014;8(3):32–4.

Elkalmi R, Hassali MA, Al-Lela OQ, JawadAwadh AI, Al-Shami AK, Jamshed SQ. Adverse drug reactions reporting: knowledge and opinion of general public in Penang, Malaysia. J Pharm Bioallied Sci. 2013;5(3):224–8.

Hughes L, Whittlesea C, Luscombe D. Patients’ knowledge and perceptions of the side-effects of OTC medication. J Clin Pharm Ther. 2002;27:243–8.

Ahmed AM, Izham IM, Subish P. Importance of consumer pharmacovigilance system in developing countries: a case of Malaysia. J Clin Diagn Res. 2010;4(4):2929–35.

Palaian S, Alshakka M, Izham M. Developing a consumer reporting program in Malaysia: a novel initiative to improve pharmacovigilance. Pharm World Sci. 2010;32(1):2–6.

Indian Pharmacopoeia Commission (IPC). Medicines Side Effect Reporting Form (For Consumers). Available at: http://ipc.nic.in/ writereaddata/linkimages/Part%202%20of%20Appendix%2017%20ADR%20Reporting%20Form% 20for%20Consumers%20-1460554002.pdf. Accessed on 12 February 2015.

Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2006;63(2):148–56.

Fleuranceau-Morel P. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. Pharmacoepidemiol Drug Saf. 2002;11:37–44.

Potharaju HR. Reporting of adverse drug reactions by consumers: rationale and potential. Pharmbit. 2010;22(2):14–21.

US Food and Drug Administration. Direct Reporting by Consumers—First International Conference. WHO Pharmaceutical Newsletters. Available at: www.fda.gov/medwatch/safety/ ar95.pdf.

Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–234.